Influence of Hemostatic Disorder on Type II Endoleak Development After Endovascular Abdominal Aortic Aneurysm Repair
International Journal of Molecular Sciences · 04.04.2026 · 27 (7) · 3288
DOI: 10.3390/ijms27073288 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.04.2026. Verfasst von Paweł Rynio und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, Pomeranian Medical University, 70-111 Szczecin, Poland. Hauptthemen laut MEDLINE: Endoleak, Aortic Aneurysm, Abdominal, Endovascular Aneurysm Repair, Hemostasis. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Endovascular aneurysm repair (EVAR) is a widely used minimally invasive treatment for abdominal aortic aneurysms. However, postoperative type II endoleak (T2EL) remains a relevant complication associated with a risk of aneurysm rupture and the need for repeated imaging follow-up, resulting in exposure to ionizing radiation. Identification of biological factors predisposing to T2EL may improve risk stratification. This pilot study aimed to investigate whether disturbances in hemostasis are associated with early T2EL development after EVAR. A total of 103 patients treated with EVAR for symptomatic or asymptomatic abdominal aortic aneurysms in a tertiary vascular center were prospectively enrolled. Blood samples were collected preoperatively and one month postoperatively to assess fibrinogen, prothrombin fragment F1+2 (F1+2), thrombin–antithrombin complex (TAT), tissue plasminogen activator antigen (tPA), plasminogen activator inhibitor-1 (PAI-1) activity, and platelet activity. Computed tomography angiography (CTA) during follow-up was used to detect endoleaks and calculate their volume. Patients with T2EL had significantly lower levels of prothrombin fragment F1+2 and higher PAI-1 activity compared with patients without endoleak. No significant association was observed between the analyzed biomarkers and endoleak volume. These findings suggest that reduced thrombin generation and impaired fibrinolysis may contribute to endoleak formation after EVAR and warrant further investigation in larger, confirmatory studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Vascular Surgery, Pomeranian Medical University, 70-111 Szczecin, Poland.
- Department of Medical Analytics, Pomeranian Medical University, 70-111 Szczecin, Poland.
- Department of Genomics and Forensic Genetics, Pomeranian Medical University, 70-111 Szczecin, Poland.
- Department of Nursing, Faculty of Health Sciences, Pomeranian Medical University, 71-210 Szczecin, Poland.
ORCID-Profile: Dagmara Lisman, Anita Rybicka, Patryk Skórka
Zitieren
APA
Rynio, P., Kłysz, M., Samad, R., Bieniek, M., Lisman, D., Rybicka, A., Skórka, P., Lempek, P., Cnotliwy, M., Kazimierczak, A., Gutowski, P., Jastrzębska, M., & Siennicka, A. (2026). Influence of Hemostatic Disorder on Type II Endoleak Development After Endovascular Abdominal Aortic Aneurysm Repair. International Journal of Molecular Sciences, 27(7), 3288. https://doi.org/10.3390/ijms27073288
Vancouver
Rynio P, Kłysz M, Samad R, Bieniek M, Lisman D, Rybicka A, et al. Influence of Hemostatic Disorder on Type II Endoleak Development After Endovascular Abdominal Aortic Aneurysm Repair. International Journal of Molecular Sciences. 2026;27(7):3288. doi:10.3390/ijms27073288
BibTeX
@article{Rynio2026,
author = {Rynio, Paweł and Kłysz, Magdalena and Samad, Rabih and Bieniek, Marta and Lisman, Dagmara and Rybicka, Anita and Skórka, Patryk and Lempek, Paulina and Cnotliwy, Miłosław and Kazimierczak, Arkadiusz and Gutowski, Piotr and Jastrzębska, Maria and Siennicka, Aldona},
title = {Influence of Hemostatic Disorder on Type II Endoleak Development After Endovascular Abdominal Aortic Aneurysm Repair},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {7},
pages = {3288},
doi = {10.3390/ijms27073288}
}
EUVIMED